Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

Search


Order results by:     
 
Issue Title
 
Vol 6, No 3 (2013) PHARMACOECONOMIC ANALYSIS OF DOCETAXEL IN THE ADJUVANT THERAPY OF BREAST CANCER Abstract  similar documents
R. I. Yagudina, I. Yu. Zinchuk
"... 198 300 RUB for 6DAC and 1 371 184 RUB for 6FAC. Direct and indirect costs rate of the breast cancer ..."
 
Vol 6, No 3 (2013) PHARMACOECONOMIC ANALYSIS OF NEUROPROTECTIVE DRUGS IN THE TREATMENT OF ACUTE DISORDERS OF CEREBRAL CIRCULATION Abstract  similar documents
A. Yu. Kulikov, I. Yu. Zinchuk
"... to placebo at 22311 RUB and 21345 RUB, respectively. Cost effectiveness analysis, based on the clinical ..."
 
Vol 9, No 2 (2016) BUDGET IMPACT ANALYSIS OF PERAMPANEL FOR ADJUNCTIVE TREATMENT IN EPILEPSY PATIENTS 12 YEARS OF AGE AND OLDER FOR PARTIAL ONSET SEIZURES WITH OR WITHOUT SECONDARY GENERALIZATION AND PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN THE RUSSIAN FEDERATION Abstract  similar documents
V. R. Mkrtchyan, A. M. Sergeev, K. I. Pochigaeva, I. A. Shpak
"... , the adoption of perampanel is projected to increase drug costs (in millions) by RUB15.2 (1.2%), RUB76.1 (6 ..."
 
Vol 13, No 4 (2020) Evaluation of the reference value of the incremental parameter "cost-effectiveness" for Russian healthcare system Abstract  similar documents
T. S. Teptsova, N. Z. Musina, V. V. Omelyanovsky
"... to the method proposed by the WHO, WPT was 2,235,201.60 Rub for DALY in the RF; according to the hemodialysis ..."
 
Vol 6, No 4 (2013) Фармакоэкономический анализ использования лираглутида в составе комбинированной терапии в лечении сахарного диабета 2-го типа Abstract  similar documents
A. Yu. Kulikov, I. V. Novikov
"... in combination with metformin equal to 1 348368 rub, 1 161874 rub and 537331 rub for QALY in comparison ..."
 
Vol 5, No 3 (2012) COST-UTILITY ANALYSIS PATIENTS WITH LOW BACK PAIN AFTER TREATMENT INTRAOSSEOUS BLOCKADES Abstract  similar documents
M. V. Yakovlev, A. U. Kulikov, E. L. Sokov, I. E. Kornilova
"... group was 0,358 and 0,134 in the second group. The cost-utility ratio for first group was 39 090,5 RUB ..."
 
Vol 9, No 1 (2016) COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA Abstract  similar documents
G. R. Khachatryan, D. V. Fedyaev, M. V. Avxentyeva, V. S. Dombrovskiy
"... . Results. In patients with relapsed or refractory CD30-positive HL after ASCT ICER was 5,8 million rub. per ..."
 
Vol 10, No 3 (2017) Comparative pharmaco-economic analysis of using enzalutamide, abiraterone and cabazitaxel in post-docetaxel castration-resistant prostate cancer patients Abstract  similar documents
N. K. Mazina, P. V. Mazin
"... (after treatment with docetaxel) in the Russian Federation. Materials and Methods. A cost effectiveness ..."
 
Vol 9, No 4 (2016) THE COSTS OF REGIONAL ANESTHESIA WITH THE USE OF LEVOBUPIVACAINE, RACEMIC BUPIVACAINE AND ROPIVACAINE Abstract  similar documents
G. E. Ulrikh, A. V. Rudakova
"... of registration in the case of inclusion in the Essential Drugs List (0,5% R-R amp. 10 ml №10 – 947,74 RUB; 0 ..."
 
Vol 12, No 4 (2019) Pharmacoeconomic analysis of using cyclin-dependent kinase 4 and 6 inhibitors in the first line treatment of HR-positive HER2-negative advanced breast cancer Abstract  similar documents
N. A. Avxentyev, E. V. Lubennikova, M. Yu. Frolov
"... considered. Results. Mean direct medical costs of using palbociclib + letrozole were 2 082 333 RUB per ..."
 
Vol 8, No 1 (2015) PHARMACOECONOMIC ANALYSIS OF EVEROLIMUS IMMUNOSUPRESSIVE THERAPY AFTER RENAL TRANSPLANTATION Abstract  similar documents
M. V. Avxentyeva, N. A. Avxentyev, M. Yu. Frolov, E. V. Derkach
"... posttransplantation period. Results. Everolimus plus reduced-exposure cyclosporine leads to cost reduction by 161 RUB ..."
 
Vol 5, No 3 (2012) PHARMACOECONOMIC EVALUATION OF THE MEDICINAL PRODUCTS ERLOTINIB, DOCETAXEL, PEMETREXED AND GEFITINIB IN THE SECOND-LINE TREATMENT OF LOCALLY-ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER Abstract  similar documents
A. U. Kulikov
"... there are used docetaxel or pemetrexed and representatives of a class of target oral medicines – gefitinib ..."
 
Vol 9, No 1 (2016) PHARMACOECONOMIC STUDY OF LENVIMA (LENVATINIB) IN ADVANCED PROGRESSIVE RADIO IODINE REFRACTORY DIFFERENTIATED THYROID CANCER IN THE RUSSIAN FEDERATION Abstract  similar documents
M. Yu. Frolov, V. A. Rogov
"... at the same time constitute 5 213 900 000 rub. (670.5 to 1184.3 million rubles per year). Calculated unit ..."
 
Vol 10, No 2 (2017) ECONOMIC ASSESSMENT OF THE EFFECTIVENESS AND SAFETY OF THE COMMONLY PRACTICED PERIOPERATIVE ANTIBIOTIC PROPHYLAXIS (BASED ON AN EARLIER EPIDEMIOLOGICAL SURVEY OF MULTIDISCIPLINARY HOSPITALS) Abstract  similar documents
Yu. M. Gomon, A. S. Kolbin, S. V. Sidorenko, A. M. Kuzhel’, A. V. Repina, Yu. V. Lobzin, Yu. E. Balykina
"... practice (RUB 4913,67 and 17837,71 respectively). The present analysis demonstrates that the PAP ..."
 
Vol 8, No 1 (2015) BUDGET IMPACT ANALYSIS IN THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD Abstract  similar documents
A. S. Kolbin, I. A. Vilyum, M. A. Proskurin, Yu. E. Balykina
"... – to 159 153 118 rub, thus the saved means allow to treat with this strategy in addition 29 patients during ..."
 
Vol 11, No 1 (2018) CYP2D6 genotyping in the daily routine of a psychiatric hospital – pharmacoeconomic evaluation Abstract  similar documents
A. A. Kurylev, B. V. Andreev, A. S. Kolbin, O. V. Limankin
"... remains cost-effective even if the genotyping costs more than 3893.8 RUB  (199% of the current value ..."
 
Vol 14, No 1 (2021) Clinical and economic constituents of the application of dexamethasone and tocilizumab in the therapy for severe conditions in patients with COVID-19 Abstract  similar documents
O. V. Zhukova, A. L. Khokhlov
"... , respectively. The cost of the treatment course with dexamethasone was 107.45 rub., tocilizumab – 78,827.20 rub ..."
 
Vol 12, No 3 (2019) Comorbidity in elderly patients with atrial fibrillation affects the “cost of illness” Abstract  similar documents
S. V. Malchikova , N. S. Maksimchuk-Kolobova, M. V. Kazakovtseva 
"... .8 medications. Direct costs amounted to 18298.2±9440.4 RUB per patient with AF per year. Of this amount, 78 ..."
 
Vol 6, No 4 (2013) Pharmacoeconomic analysis of fluid therapy in the treatment of patients with peritonitis Abstract  similar documents
R. I. Yagudina, M. M. Murashko
"... пациентов использованы для оценки эффективности. Коэффициенты «затраты-эффективность» составили 440 759 руб ..."
 
Vol 6, No 1 (2013) PHARMACOECONOMIC STUDY OF SKIN TESTS IN THE DIAGNOSTICS OF TUBERCULOSIS INFECTION Abstract  similar documents
R. I. Yagudina, I. Yu. Zinchuk
"... составило 122.687 руб. против 3.646.833 руб. и 551.150 руб. соответственно. Таким образом, с точки зрения ..."
 
Vol 6, No 4 (2013) Pharmacoeconomic analysis of Anti-inhibitor coagulant complex (AICC) in the treatment of inhibitor hemophilia Abstract  similar documents
R. I. Yagudina, I. Yu. Zinchuk
"... России, составит 2,838 млрд руб., 2,608 млрд руб. и 2,283 млрд руб. для монотерапии ЛС Эпртаког альфа ..."
 
Vol 9, No 2 (2016) PHARMACOECONOMIC ANALYSIS OF VESOMNI (SOLIFENACIN AND CONTROLLED RELEASE TAMSULOSIN) TREATMENT OF STORAGE SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA Abstract  similar documents
N. A. Avxentyev, M. Yu. Frolov
"... случае расходы на одного пациента в год в среднем составляют 22 тыс. руб. (экономия около 2 тыс. руб. по ..."
 
Vol 11, No 3 (2018) Pharmacoeconomic analysis of using belimumab for the treatment of systemic lupus erythematosus Abstract  similar documents
A. G. Tolkushin, N. L. Pogudina
"... затрат составила примерно 8,84 млн руб. и 17,72 млн руб. (из них 4,05 млн руб. и 5,58 млн руб. – прямые ..."
 
Vol 14, No 1 (2021) Analysis of acquisition and the monthly cost of antihypertensive therapy with modern fixed-dose combinations in the Far Eastern Federal District Abstract  similar documents
M. S. Soboleva, E. E. Loskutova
"... ценовом диапазоне 100–500 руб. пользуются комбинации: атенолол+хорталидон и бисопролол+амлодипин. В группе ..."
 
Vol 10, No 3 (2017) Evaluation of economic damage from multiple sclerosis in the city of Ufa, Russia Abstract  similar documents
E. V. Ivanova, K. Z. Bachtiyarova
"... за год теряет 428 222 026,35 руб., при этом основную долю составляют прямые медицинские затраты, из ..."
 
Vol 7, No 3 (2014) ASSESSMENT OF NECESSARY FINANCIAL EXPENSES ON THE DRUG SUPPLY OF THE PATIENTS WITH ORPHAN DISEASES IN THE RUSSIAN FEDERATION Abstract  similar documents
M. V. Sura, K. V. Gerasimova, V. V. Omelyanovskiy, M. V. Avksentyeva
"... фармакотерапию 24 редких заболеваний составили 15,73 млрд руб. в год (6,36 млрд руб. на детей и 9,37 млрд руб. на ..."
 
Vol 5, No 3 (2012) CLINICAL AND ECONOMIC BENEFITS OF HUMAN INSULIN ANALOGUESUSE Abstract  similar documents
E. E. Arinina, M. A. Rashyd
"... ® на Левемир® /НовоРапид®, которые составили 21774 руб. на одного пациента в год, а предотвращенные ..."
 
Vol 8, No 2 (2015) CLINICAL AND ECONOMIC ANALYSIS OF THE USE OF DIFFERENT TYPES OF SYSTEMS OF VENOUS ACCESS IN THE TREATMENT OF CHILDREN WITH CANCER Abstract  similar documents
Maksim Yur'evich Rykov, Vladimir Georgievich Polyakov
"... период лечения пяти внешних центральных венозных катетеров необходимо затратить 227250000 руб., а на ..."
 
Vol 8, No 2 (2015) PHARMACOECONOMIC STUDIES TREATMENT OF PATIENTS WITH INJURIES IN THE DEPARTMENT OF ANESTHESIOLOGY AND RESUSCITATION WITH METHODS ANALYSIS THE COST OF ILLNESS Abstract  similar documents
Anton Alexandrovich Kasatkin
"... пациентов с тяжестью травмы 31 балл и составила 11000 и 5600 руб., соответственно. Затраты на лечение ..."
 
Vol 9, No 2 (2016) METASTATIC COLORECTAL TREATMENT COSTS OF USING TARGETED DRUGS IN SECOND AND FURTHER LINES THERAPY Abstract  similar documents
N. A. Avxentyev, E. V. Derkach, E. A. Pyadushkina, M. D. Ter-Ovanesov
"... . руб. / месяц сохраненной жизни против 136 тыс. руб./месяц для цетуксимаба и 310 тыс. руб. / месяц для ..."
 
Vol 12, No 2 (2019) Comparative modeling of socio-economic burden among smokers, nonsmokers and former smokers Abstract  similar documents
E. V. Radchenko, A. S. Kolbin
"... трудоспособности) - составило 510,6 млрд руб. Разница между курильщиками и равной по величине популяцией некурящих ..."
 
Vol 8, No 4 (2015) THE COST OF NUTRITION ALTERNATIVES FOR PREMATURE INFANTS IN RUSSIA Abstract  similar documents
K. V. Gerasimova, M. V. Avxentyeva, I. A. Belyaeva
"... 41,14 руб. соответственно. Стоимость одного предотвращенного случая НЭ благодаря вскармливанию ГМ ..."
 
Vol 13, No 4 (2020) The social-economic burden of spinal muscular atrophy in Russia Abstract  similar documents
A. S. Kolbin, D. V. Vlodavets, A. A. Kurylev, Yu. Ye. Balykina, M. A. Proskurin, S. A. Mishinova, O. Yu. Germanenko, N. Yu. Kolbina
"... типа. В сценарии 1 бремя СМА в РФ составило 2,37 млрд руб./год. (2,38 млн руб./пац./год) наибольшую ..."
 
Vol 12, No 2 (2019) Pharmacoeconomic analysis of ceftazidime+avibactam (Zavicefta®) in the treatment of sepsis caused by carbapenem-resistant enterobacteria Abstract  similar documents
S. V. Nedogoda, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova
"... % против 34,8% соответственно, р=0,031). Стоимость курса цефтазидим+авибактам составила 228,3 тыс. руб ..."
 
Vol 12, No 4 (2019) Pharmacoeconomic analysis of using biological agents for uncontrolled moderate-to-severe atopic asthma in the Russian Federation Abstract  similar documents
S. K. Zyryanov, I. N. Diyakov, S. N. Avdeev
"... потратить на 463 805 руб., или на 24,80% меньше, чем при использовании реслизумаба, и на 382 640 руб., или ..."
 
Vol 5, No 1 (2012) PHA RMA COE CONOMI CAL EVALUATION OF MULTIPLE MYELOMA TREATMENT WITH REVLIMID (LENALIDOMIDE ) IN THE RUSSIAN FEDE RATION Abstract  similar documents
R. Yagudina, A. Kulikov, B. Misikova
"... терапии, а Велкейда – в третьей составили 468 110,84 и 498 771,21 руб. в первом и во втором сценариях ..."
 
Vol 6, No 4 (2013) Pharmacoeconomical assessment of сerebrolysin in the treatment of the acute disturbances of cerebral circulation Abstract  similar documents
A. Yu. Kulikov, L. A. Komarov
"... церебролизина для лечения ОНМК по ишемическому типу позволяет сэкономить примерно 1,47 млрд руб. в год в расчете ..."
 
Vol 10, No 2 (2017) CLINICAL AND ECONOMIC EVALUATION OF CHRONIC DISEASE TREATMENT: A DISCREPANCY BETWEEN THE TRADITIONAL PHARMACOECONOMIC AND SOCIO-ECONOMIC ANALYSES Abstract  similar documents
O. V. Zhukova, S. V. Kononova
"... 873,00 руб. до 1515,39 руб., имеющих место при использовании противоастматических схем, включающих ..."
 
Vol 11, No 3 (2018) Determination of a willingness-to-pay threshold and decision-making in financing the healthcare technologies Abstract  similar documents
T. S. Teptsova, T. P. Bezdenezhnyh, V. K. Fedyaeva, N. Z Musina, G. R. Hachatryan, V. V. Tarasov
"... дополнительно предотвращенного DALY составит 313 878,21 руб., а стоимость одного дополнительно сохраненного QALY ..."
 
Vol 9, No 3 (2016) METHOD «COST-EFFECTIVENESS» IN EVALUETION OF ATIBIOTIC TREATMENT OF ACYTR OBSTRUCTIVE BRONCHITIS IN CHILDREN IN HOSPITAL Abstract  similar documents
O. V. Zhukova, S. V. Kononova
"... коэффициента ICER было получено для Сумамеда (Teva) и составило 39 367,50 руб. Для Сумамеда было характерно и ..."
 
Vol 11, No 2 (2018) Clinical and economic efficiency of the loop ileostomy closure by various methods Abstract  similar documents
A. V. Veselov, S. I. Achkasov, O. I. Sushkov, A. I. Moskalev, I. S. Lantsov
"... пациента в группах 1 и 2 составили 131704,90 руб. и 145473,70 руб. соответственно, в то время как в группе ..."
 
Vol 12, No 4 (2019) Optimization of drug supply for patients with malignant neoplasms in a region of the Russian Federation Abstract  similar documents
A. V. Nikitina, F. V. Gorkavenko, Y. S. Saybel, M. V. Avxentyeva, M. S. Sura, D. V. Fedyaev
"... для лечения солидных ЗНО в базовом сценарии 352,2 млн руб. за 5 лет возможно высвобождение 69,4 млн ..."
 
Vol 13, No 4 (2020) Pharmacoeconomic analysis of first-choice antimicrobial drugs prescribed for outpatient treatment of non-severe community-acquired pneumonia Abstract  similar documents
V. G. Deriushkin, A. P. Ternavskii, S. V. Gatsura
"... средняя цена за курс лечения ВБП составила 617,50 руб. Сравнение реальных средних затрат на курс ..."
 
Vol 10, No 3 (2017) Initiation and intensification of insulin therapy in patients with type 2 diabetes mellitus: a budget impact analysis Abstract  similar documents
E. V. Biryukova, V. I. Ignat’eva
"... инсулинотерапии 20%) годовые затраты на закупку инсулинов для моделируемой популяции составили 22,5 млн руб ..."
 
Vol 11, No 2 (2018) Pharmacoeconomic analysis of treatment with nilotinib as the second line therapy in patients with chronic myeloid leukemia Abstract  similar documents
N. A. Avxentyev, M. Yu. Frolov, A. S. Makarov
"... » по сравнению с рассматриваемыми альтернативами (99 573 руб., 118 711 руб., 157 692 руб. на 1 месяц ..."
 
Vol 5, No 2 (2012) PHARMACOECONOMIC STUDY OF PRIMARY OPEN-ANGLE GLAUCOMA TREATMENT WITH COMBINATIONS OF PROSTAGLANDIN ANALOGUES AND BETA-BLOCKERS Abstract  similar documents
A. Yu. Kulikov, V. G. Serpikov
"... сравнении с препаратом Ксалаком, Дуотрав предоставляет экономию денежных средств в размере 1 721 руб. на ..."
 
Vol 7, No 3 (2014) MODELI NG CLINICAL AND ECONOMIC OUTCOMES OF TESTING FOR LTBI WITH T-SPOT.TB IN IMMUNOCOMPROMISED CHILDREN Abstract  similar documents
V. I. Ignatyeva, M. V. Avxentyeva, V. V. Omelyanovsky, G. R. Khachatryan
"... затраты на всю когорту составят 1,71 млн руб. при использовании реакции Манту (в т.ч. затраты на ..."
 
Vol 8, No 1 (2015) SOCIAL AND ECONOMIC BURDEN OF FIVE NATURAL FOCAL INFECTIONS IN THE RUSSIAN FEDERATION Abstract  similar documents
A. E. Platonov, N. A. Avksentyev, M. V. Avksentyeva, E. V. Derkach, O. V. Platonova, A. V. Titkov, N. M. Kolyasnikova
"... инфекционных заболеваний, составляла, по ценам 2011 г., 909 млн. руб., большая часть из них приходится на ..."
 
Vol 10, No 2 (2017) COST-EFFECTIVENESS OF VILANEROL / UMECLIDINIUM VERSUS TIOTROPIUM IN SEVERE AND VERY SEVERE COPD Abstract  similar documents
E. G. Kosolapov, F. S. Kochenkov, N. L. Pogudina, D. V. Blinov
"... + умеклидиния бромид и тиотропия бромид составила 32 753 руб. и 37 641 руб. соответственно. Таким образом ..."
 
Vol 11, No 1 (2018) Antimicrobial therapy of community-acquired pneumonia in a hospital setting (clinical and economic aspects) Abstract  similar documents
O. V. Zhukova, O. V. Ruina, M. V. Khazov, S. V. Romanov
"... средней степени тяжести составили: 10,5 дней и 731,65 руб. для цефтриаксона; 9,1 дней и 1353,00 руб. – для ..."
 
1 - 50 of 70 Items 1 2 > >> 

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default articles containing any term in the query are returned (i.e., OR is implied)
  • Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
  • Combine multiple words with AND to find articles containing all terms; e.g., education AND research
  • Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
  • Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)